anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to a menstruation regulating and reproduction assisting paste and a preparation method thereof. The menstruation regulating and reproduction assisting paste comprises 80-120g of trogopterus dung, 20-40g of lanceleaf anisetree root, 40-60g of spina gleditsiae, 90-110g of pangolin scales, 85-105g of corydalis tuber, 45-55g of rhizoma zingiberis, 42-58g of common fennel, 38-62g of myrrh, 89-111g of rhizoma ligustici wallichii, 92-108g of angelica, 16-24g of cinnamon, 85-115g of magnetite, 41-59g of cattail pollen, 600-900g of colophony, 190-250g of camphor, 26-34g of propolis and 48-55g of composite inorganic far infrared health care material. The menstruation regulating and reproduction assisting paste plays roles in improving the periphery micro circulation, accelerating the blood flow, promoting the drug absorption and enhancing the immune functions so as to achieve the aims of diminishing inflammation and relieving pain. The magnetic therapy can improve the micro circulation, improve the permeability of organizations and accelerate the absorption of inflammatory exudates so as to have the functions of inflammation diminishment and detumescence. The traditional Chinese medicine for promoting the circulation of qi, invigorating the blood circulation, regulating the menstrual function and relieving the pain is combined with the far infrared material, the magnetic therapy and acupoint therapy, and therapeutic effects are superimposed, thereby greatly improving the medicament transdermal absorptive amount and redoubling the efficacy compared with the single far infrared and magnetic therapy or oral medication. The menstruation regulating and reproduction assisting paste has good curative effects on irregular menstruation and dysmenorrheal caused by qi depression to blood stasis and cold obstruction to uterus vessels and infertility caused by chronic pelvic inflammatory diseases.
Irinotecan-induced severe diarrhea (IISD) not only limits irinotecan's application but also significantly affects patients' quality of life. However, existing animal models often inadequately represent the dynamics of IISD development, progression, and resolution across multiple chemotherapy cycles, yielding non-reproducible and highly variable response with limited clinical translation. Our studies aim to establish a reproducible and validated IISD model that better mimics the pathophysiology progression observed in patients, enhancing translational potential. We investigated the impact of dosing regimens (including different dose, infusion time, and two cycles of irinotecan administration), sex, age, tumor-bearing conditions, and irinotecan formulation on the IISD incidence and severity in mice and rats. Lastly, we investigated above factors' impact on pharmacokinetics of irinotecan, intestinal injury, and carboxylesterase activities. In summary, we successfully established a standard model establishment procedure for an optimized IISD model with highly reproducible severe diarrhea incidence rate (100%) and a low mortality rate (11%) in F344 rats. Additionally, the rats tolerated at least two cycles of irinotecan chemotherapy treatment. In contrast, the mouse model exhibited suboptimal IISD incidence rates (60%) and an extremely high mortality rate (100%). Notably, dosing regimen, age and tumor-bearing conditions of animals emerged as critical factors in IISD model establishment. In conclusion, our rat IISD model proves superior in mimicking pathophysiology progression and characteristics of IISD in patients, which stands as an effective tool for mechanism and efficacy studies in future chemotherapy-induced gut toxicity research.
Subjects will be given a one-time infusion of AFNT-211 starting at dose level 1 and monitored for 28 days (DLT period). Each cohort will enroll 2-4 subjects at different dose levels for a total of 20 subjects in the escalation portion. The optimal biological dose and recommended phase 2 dose will be determined.
PROBLEM TO BE SOLVED: To obtain a single component type treating agent for hair which reforms the texture of hair to that of healthy hair and makes the effect sustainable by treating hair with the treating agent for hair containing a specific polymeric compound and forming a film on the surface of the hair. SOLUTION: This treating agent for hair contains polymeric compounds, e.g. copolymers of alkyl acrylate, copolymers of alkyl acrylate and styrene, copolymers of vinyl crotonate or acetate and vinyl neodecanate, bisphenol A type epoxy resin oleinate, copolymers of vinyl methyl ether and ethyl maleinate and polyvinylbutyrals. The polymeric compounds are preferably formulated in an amount of about 0.01-5.0wt.%, particularly about 0.1-3.0wt.%, based on the whole weight of the treating agent for hair. Because films are formed on the surface of hair by the treating agent, the outfolw of matrices present in the hair is preventable. By this process, hair is prevented from the damage and the texture of injured hair is improved. Cut and split hairs are also preventable. The effect is more excellent than usual hair treatment.
Head and neck squamous cell carcinoma (HNSCC) is painful, and perineural invasion (PNI) has been associated with the worst pain. Pain due to HNSCC is diverse and may vary based on clinicopathological factors. This study aims to characterize different pain patterns linked with PNI, its influence on daily functioning, and gain insights into molecular changes and pathways associated with PNI-related pain in HNSCC patients. We conducted a cross-sectional study across 3 medical centers (n = 114), assessing pain phenotypes and their impact on daily functioning using 2 self-reported pain questionnaires, given to patients prior to their cancer surgery. Furthermore, we conducted RNA-seq analysis utilizing the The Cancer Genome Atlas dataset of HNSCC tumor from patients (n = 192) to identify genes relevant to both PNI and pain. Upon adjusting for demographic and clinicopathological variables using linear regression models, we found that PNI independently predicted function-evoked pain according to the University of Calfornia San Francisco Oral Cancer Pain Questionnaire, as well as the worst pain intensity reported in the Brief Pain Inventory. Distinct pain patterns were observed to be associated with daily activities in varying manners. Our molecular analyses revealed significant disruptions in pathways associated with the extracellular matrix structure and organization. The top differentially expressed genes linked to the extracellular matrix are implicated in cancer development, pain, and neurodegenerative diseases. Our data underscore the importance of properly categorizing pain phenotypes in future studies aiming to uncover mechanistic underpinnings of pain. Additionally, we have compiled a list of genes of interest that could serve as targets for both cancer and cancer pain management. PERSPECTIVE: PNI independently predicts function-evoked pain. Different pain phenotypes affect daily activities differently. We identified a list of candidate genes involved in the extracellular matrix structure and function that can be targeted for both cancer and cancer pain control.
Renal impairment is a risk factor for myopathy and rhabdomyolysis. Monitor all patients with renal impairment for development of myopathy. Renal impairment does not affect the plasma concentrations of atorvastatin calcium, therefore there is no dosage adjustment in patients with renal impairment [see Error! Hyperlink reference not valid.and Error! Hyperlink reference not valid.] .
Participants received placebo matched to SAR440340 administered as 2 subcutaneous (SC) injections every 2 weeks (Q2W). Participants were treated for a minimum of 24 weeks and up to a maximum of 52 weeks (last dose administered at Week 50, End of Treatment (EOT) visit occurred 2 weeks after last administration of IMP i.e., at Week 52).
A nano-emulsion composition for skin care application is provided. The nano-emulsion composition being oil-in-water composition. The nano-emulsion composition includes at least one oil, at least one hydrophilic compound to create an aqueous phase, at least one water soluble phytoactive compound, and at least one oil soluble phytoactive compound. The nano-emulsion composition also includes a combination of polyglycerol fatty acid esters as emulsifiers. The combination of polyglycerol fatty acid esters comprises a first polyglycerol fatty acid ester and a second polyglycerol fatty acid ester in a ratio of 1:1. Further the nano-emulsion composition includes at least one preservative. The nano-emulsion composition being a low viscous fluidic vehicle to be used as serum, micellar water, facial cleanser etc. The nano-emulsion composition being capable of retaining high storage stability over a wider temperature range. The invention also provides a skin care composition and a cosmetic comprising the nano-emulsion composition.
Swallowing is not only an important function for life maintenance, but also for quality of life improvement. Statistics revealed that subjects with intellectual disability or multiple disabilities have problems in controlling muscle tone and maintaining posture. In such circumstances, these subjects experience problems during feeding or eating. The adjustment of seat inclination would help in feeding/eating process. However, the proper inclination angle should be evaluated by medical professionals, however, most caregivers do not know the influence of improper positioning therefore subjects suffer from possible choking risks. The aims of this study were to investigate the timing and coordination of swallowing and respiration in 4 different seat inclination angles, with liquid and bolus. In the first stage, the investigators intend to use a self-developed wearable device to measure the submandibular muscle surface EMG, the movement of thyroid cartilage and respiratory status of nasal cavity. This particular program could auto-analysis the onset and offset of duration, and the excursion and strength of thyroid cartilage will be calculated when it was moving, coordination between breathing and swallowing was also included. The measurement would be done in four seat inclination angles (5, 15, 30, 45) for each subject. The data collected between different conditions would be compared, and suggestions of ideal angles during swallowing would be made. The second stage is the design and development of a feedback-controlled seat angle adjustment device, based on the data collected. The results of this study would serve as the clinical guidelines for proper feeding positions for different populations and for different food contents. The ergonomic data would also provide references for assistive technology professionals and practitioners in device design and development.
NEW MATERIAL:The compound of formulaI(R1 is alkyl or alkoxy; l is 0 or 1-3; R2 is alkyl). EXAMPLE:trans-1-( Benzenesulfonyloxy )-2-( 4-isopropyl-cyclohexyl )-2-ethanone. USE:Remedy for hyperlipemia. Antiphlogistic agent and immunoregulating agent. It has esterase-inhibiting, chymotrypsin-inhibiting and antilipemic activities. PROCESS:The compound of formulaIcan be prepared by reacting the trans- diazo compound of formula II with the compound of formula III (m is 0, 1 or 2). The reaction is carried out usually in a solvent (e.g. dimethyl ether, THF, etc.), and the amount of the compound of formula III is preferably more than equimolar to the compound of formula II. The compound of formulaIexhibits very weak toxicity when used as a remedy for hyperlipemia which is a dangerous factor of various geriatric diseases. The characteristics of the compound are extremely wide safety range and high safety compared with the conventional remedies for hyperlipemia.
Our hospital milk bank provides pasteurized donor human milk (PDHM) to very low birth weight (VLBW) infants without sufficient mother's milk, with the overall aim of lowering the risk of necrotizing enterocolitis in this population. However, with the introduction of PDHM in our setting, rates of suboptimal weight gain have increased (60.2% to 65.7%). This is likely due to the fact that PDHM is often lower in energy and protein than preterm mother's own milk. One solution to delivery adequate nutrition in this VLBWs receiving PDHM, is targeted fortification, which involves measurement of the macronutrient content of human milk, and adding extra macronutrients to reach nutrient goals. In this proposed study, we will conduct a pilot randomized controlled trial of a modified targeted fortification versus standard care. This study will include preterm VLBW infants (\<1500g), without congenital conditions resulting in growth restriction, and receiving \>25% of PDHM use in the first week of life. 40 patients in each arm will be recruited over a period of 2 years. The intervention group will receive a modified targeted fortification, consisting of selection of high fat PDHM (3.8g/dL or more) with the addition of protein fortification of 0.67g/dL from week 2 of life until a gestational age of 37 weeks or hospital discharge, whichever earlier. The control group will receive usual regular PDHM with standard fortification using human milk fortifier as per current practice. The primary outcome is the rate of suboptimal growth (drop in weight z-score from birth ≥0.8) at discharge or 37 weeks. Secondary outcomes include body composition, feed tolerance, and morbidity outcomes.
A method for smart image protocoling includes, using a medical imaging device, obtaining, using a first medical imaging sequence, a first set of medical images of a patient. Anatomical and, if present, disease features are extracted from the first set of medical images. A machine learning trained algorithm is used to determine, in real time, and based on the extracted anatomical and/or disease features, whether a desired medical imaging goal is achieved for the patient. In response to determining that the desired medical imaging goal is achieved, at least one image from the first set of medical images is output as a final image. In response to determining that the desired medical imaging goal has not been achieved, the machine learning trained algorithm is used to select a second medical imaging sequence. A second set of medical images of the patient is obtained using the second medical imaging sequence. The above outlined procedures will be repeated until the final imaging goal is achieved for a patient.
BACKGROUND: Work-related musculoskeletal disorders (WMSDs), also referred to as work-related musculoskeletal injuries (MSKIs), cause surgeons pain and discomfort. Implementing ergonomics in the operating room has helped reduce such symptoms. However, there are still many issues that surgeons face when dealing with medical instruments, especially among female surgeons or surgeons with smaller hands.
METHODS: The Cochrane methodology for performing a systematic review was utilized to search five databases for pertinent literature based on the study question "Do female surgeons or surgeons with smaller hand size, who use surgical instruments have an increased risk of musculoskeletal disorders and discomfort compared to male or larger handed surgeons?". The literature search strategy was designed around the three conceptual domains of surgeons/surgery, smaller hand size, and instrumentation. We searched PubMed, Embase.com, CINAHL Plus with Full Text (EBSCOhost), Scopus, and Web of Science Core Collection. This exploration identified 2165 research publications, and after specific inclusion and exclusion criteria, 19 studies were included in the systematic review. Risk of bias analysis was conducted to assess the quality of the included studies. After conducting a heterogeneity test, a meta-analysis was not performed due to high heterogeneity.
RESULTS: Using certain surgical instruments presents challenges in the form of MSKIs for female and smaller-handed surgeons. Studies showed that 77% of females and 73% of surgeons who wear < 6.5 glove size report musculoskeletal issues ranging from difficulty of use to pain. Difficulties using surgical instruments and reported injuries have a greater impact on surgical trainees which might deter interest in surgical fields for future proceduralists. Recommendations for improved ergonomic tool design are suggested by some of the included studies to help tackle the MSKIs that surgeons face when performing operations.
CONCLUSIONS: The number of female surgeons has increased substantially in the last decade. Hence, there exists an urgent need to address the major challenges they encounter by focusing on this specific aspect of workplace safety and health to mitigate injury. Doing so will yield a productive environment while simultaneously protecting the health and safety of both surgeons and patients.
SYSTEMATIC REVIEW REGISTRATION: The study protocol was registered on PROSPERO (ID: CRD42022283378).
The invention relates to a preparation method of stomach disease treating powders. Stomach disease is a common frequently-occurring disease and the cause is both external and internal. Serious stomach disease can harm the human body health and is hard to be cured. The invention uses theory of the traditional Chinese medicine, takes incompatible medicines in the traditional Chinese medicine and adopts modern scientifically biological technology to process the incompatible medicines to make the product which can treat stomach disease, reaching the effect of half the work with double results. The preparation method of stomach disease treating powders makes incompatible medicines in the traditional Chinese medicine such as seaweed, liquorice, euphorbia pekinensis, Pemphis Forst, Euphorbia kansui, radix aconite, Bletilla striata, radix ampelopsis, Pinellia ternate, Tribulus terrestris, Snakegourd Fruit and etc. into prescription and compatibility. The above mentioned medicines are ground, sterilized and added with Mucor sufu and Aspergillus oryzae for starter propagation, fermentation and enzymolysis. Under the effect of enzymolysis, the internal molecular structures of the incompatible medicines are decomposed to neutralize toxic and side effects of the medicines and the decomposition and separation effect of the medicines generates new substances to gain effect multiplication of the stomach disease treating powders, to reach multiple purposes and to promote the prescription incompatible medicines of the traditional Chinese medicine to be used scientifically by modern technologies.
Botulinum neurotoxins (BoNTs), derived from Clostridium botulinum, have been employed to treat a range of central and peripheral neurological disease. Some studies indicate that BoNT may be beneficial for pain conditions as well. It has been hypothesized that BoNTs may exert their analgesic effects by preventing the release of pain-related neurotransmitters and neuroinflammatory agents from sensory nerve endings, suppressing glial activation, and inhibiting the transmission of pain-related receptors to the neuronal cell membrane. In addition, there is evidence to suggest that the central analgesic effects of BoNTs are mediated through their retrograde axonal transport. The purpose of this review is to summarize the experimental evidence of the analgesic functions of BoNTs and discuss the cellular and molecular mechanisms by which they can act on pain conditions. Most of the studies reviewed in this article were conducted using BoNT/A. The PubMed database was searched from 1995 to December 2022 to identify relevant literature.
Immunocompromised children with cancer receiving chemotherapy or undergoing hematopoietic stem cell transplant (HSCT) are at high risk of infections. Invasive fungal infection (IFI) is a significant cause of morbidity and mortality. The incidence of IFI from 5.3% to 24% and the mortality rate from 18.6% to 67.6%. Definite diagnosis of fungal infection in immunocompromised patients is particularly challenging. However, the clinical presentation of IFI is not specific, especially in pediatric patients. The culture of blood is the major method to diagnose proven IFI, but the results are mostly negative, and culture is time consuming. New nonculture-based methods, including antigen-based assays, and molecular detection of fungal DNA which may allow early diagnosis and treatment of fungal infection. Molecular techniques, including DNA sequencing and polymerase chain reaction (PCR). These techniques have become more available in many laboratories; however, it lacks methodological standardization, and the results vary widely among laboratories. More attention paid to the biomarkers. 1, 3- β -D- glucan (BDG) is a component of the fungal cell wall and therefore it considered a pan-fungal detection method. Traditional biomarkers as C-reactive protein (CRP) and procalcitonin (PCT) have also been evaluated for their abilities in distinguishing IFI and other infections. In neonates, CRP levels were significantly higher in fungemia than in bacteremia, in adult patients, there was not a significant difference between the candidemia and bacteremia groups. The PCT value was markedly lower in the fungal infection group than in the bacteremia group at the onset of fever.
The control group will continue to receive the treatment as usual in their intervention resources. At the end of the 15-week control period they will receive the intervention.
Within the past decade, there has been increasing recognition of the limitations and risks of opioid therapy for chronic pain, spurred by the U.S.' widespread epidemic of opioid misuse. Within the clinical context, concerns about long-term opioid therapy persist due to limited evidence of efficacy and the occurrence of medication misuse/abuse (termed aberrant drug-related behavior). Psychosocial approaches, particularly self-management strategies such as cognitive-behavior therapy (CBT), have been found to be efficacious for the treatment of chronic pain. However, most chronic pain patients are not exposed to comprehensive psychosocial interventions, due to factors including pain specialty physicians' lack of familiarity with and time to provide behavioral treatments and insufficient payer coverage for these therapies. To address these public health concerns, this study developed, implemented and evaluated an innovative, web-based CBT intervention for the treatment of chronic pain tailored to the specific needs of patients who are prescribed opioids and present with aberrant behavior. The development of this interactive, web-based intervention was informed by iterative feedback from pain experts and chronic pain patients. In a randomized, controlled trial, chronic pain patients receiving opioid therapy at a pain specialty practice were assigned to receive 12 weeks of either treatment-as-usual (TAU; n=55) or treatment-as-usual plus the web-based intervention (Web-CBT; n=55). The trial evaluated the relative effectiveness of these treatments on the primary outcomes of pain severity, pain interference and aberrant opioid-taking behavior, and the secondary outcomes of pain catastrophizing and pain-related Emergency Department visits. Additional analyses explored the impact of the intervention on several supplementary outcomes, such as various categories of activities, psychiatric distress and positive affect, and examined hypothesized mediators of treatment outcome, including quality of life, social support and expectations about the future.